|
|
|
Winning Global Customers through Innovative Quality Pharmaceutical Products
|
|
|
|
|
|
Ind-Swift had recognized
the pivotal role that will be played by the R&D much ahead
of time and therefore, in spite of several hurdles faced by
the Company earlier, it continued to invest in R&D. Today
Company's modern R&D set up is the result of that wisdom.
Company is well placed to face the post 2005 scenario which
still confounds many domestic companies.
R&D Focus
In the patent
free environment, where there are a plethora of bulk drug
manufacturers, the Company has decided to concentrate on those
molecules, manufacture of which requires complex chemistry and
several reactions steps. This way a lot of fringe players are
eliminated and the market is less crowded. A strong R&D
set up is inevitable to achieve this.
As a result, we
have built up considerable R&D strengths, centered on a
knowledge base pool of over 80 scientists and technical
personnel are working towards the common goal of achieving
excellence in all spheres of activities, be it development of
new molecule, changes in the process resulting in cost
reduction or improvement in the quality of products. As a
result of its R&D initiatives, the Company has been able
to introduce several new molecules first time in India. ISLL
is a technology driven company. The technologies are not only
cost effective, but also give quality products, consistently
with higher purity. ISLL has been investing aggressively in
its R&D activities, to the level of almost 6% of its
turnover.
R&D
Activities
Our major strengths and core
competencies lay in the development and commercialization of
Active Pharmaceutical Ingredients (API) in line with
regulatory and quality requirements.
- Process optimisation and improvement.
|
- Research for APIs/ advance intermediates and fine
chemicals
|
- Development of non-infringing processes for
promising molecules
|
|
- Pilot studies of new molecules for clients.
|
Future Directions:
R&D
will play a more significant role in future. While development
of new molecules will remain its core activity in the post
patent era the Company will also focus on alternate and
non-infringing routes for the drugs whose patent will expire
in coming years.
To enter the regulated markets like
USA, EU, Australia, and New Zealand, the Company is focusing
on getting its manufacturing plant approved by regulatory
agencies like USFDA, TGA and MCA.
A new R&D Center
with investment of US$ 5 Million is already planned in Mohali
with a focus to develop NCEs.
Creative spirit,
dedicated effort and application of new technology, form the
basis for innovation, which the pharmaceutical industry
requires for success in today's research driven environment.
Ind-Swift itself is at the forefront of science in utilizing
novel methodologies for the achievement of its
goal.
|
|
|
|